View Post

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

In In The News by Barbara Jacoby

By: Da Hee Han, PharmD From: Celltrion and Teva announced that the Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications. Patients should be selected for treatment based on an FDA-approved companion diagnostic for a trastuzumab product. Specifically, Herzuma is approved to treat: Adjuvant breast …